[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 202
1. Manapov F: Central nervous system relapse continues to be a therapeutic challenge in extensive disease small-cell lung cancer patients with initial symptomatic brain metastases and good response to chemoradiotherapy. J Neurooncol; 2010 Jul;98(3):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms of the effect on the central nervous system dominated the course of the cancer disease, whereas the primary tumor mass remained in complete remission in all four patients until the end of the follow-up period.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2004 Dec;23(12):1671-6 [15601558.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(2):91-4 [11373886.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1827-34 [18311784.001]
  • [Cites] Am J Clin Oncol. 1997 Apr;20(2):125-7 [9124183.001]
  • [Cites] Cancer. 1979 Nov;44(5):1885-93 [227582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):2025-8 [3021695.001]
  • [Cites] Ann Intern Med. 1987 Mar;106(3):386-9 [3028222.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):801-6 [14770437.001]
  • [Cites] Onkologie. 2007 Jul;30(7):361-6 [17596744.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):916-22 [2544685.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3400-8 [11013281.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):484-8 [12507082.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2079-83 [16648509.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):277-80 [16614943.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):247-254 [28306437.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):753-9 [10470420.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1724-9 [12175688.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):240-3 [17056192.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):29-32 [9488124.001]
  • [Cites] J Neurooncol. 2000 Jul;48(3):243-8 [11100822.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6):652-5 [18520807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 May;14(5):861-5 [2834310.001]
  • (PMID = 20013147.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


2. Glodkowska E, Bialas A, Jackowska T: [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia]. Med Wieku Rozwoj; 2007 Apr-Jun;11(2 Pt 1):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
  • INTRODUCTION: Acute lymphoblastic leukaemia (ALL) is one of the most common cancers in children.
  • The stratification was by age, leukocyte count, cytogenetic changes, early response to prednisone therapy and bone marrow remission.
  • RESULTS: out of the 100 patients qualified for treatment regimens according to the ALL-IC 2002 protocol, 97 entered remission, 11 died and 3 had a relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Risk Assessment / methods
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Infant. Male. Poland. Prednisolone / therapeutic use. Prednisone / therapeutic use. Prognosis. Remission Induction. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625285.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol; PVDA protocol
  •  go-up   go-down


3. Jones LK, Saha V: Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol; 2005 Aug;130(4):489-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia positive acute lymphoblastic leukaemia of childhood.
  • On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment.
  • A few respond quickly to treatment and achieve long-term remission.
  • Some fail to achieve remission after induction and the majority respond slowly to treatment.
  • Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Child. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction / methods. Stem Cell Transplantation. Transplantation, Homologous

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098062.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 123
  •  go-up   go-down


Advertisement
4. Aregawi DG, Sherman JH, Douvas MG, Burns TM, Schiff D: Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle Nerve; 2008 Sep;38(3):1196-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia.
  • We describe a patient in remission from acute lymphoblastic leukemia who developed a painless common peroneal neuropathy.
  • In selected patients presenting with peripheral neuropathy, MRI and PET scan can be helpful in the diagnosis of peripheral nerve infiltration.
  • [MeSH-major] Leukemic Infiltration / etiology. Peroneal Neuropathies / etiology. Peroneal Neuropathies / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Muscle Nerve. 2009 Mar;39(3):413-4 [19208400.001]
  • (PMID = 18642385.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Schneider P, Vasse M, Corbière C, Legrand E, Marie-Cardine A, Boquet C, Cazin L, Vannier JP: Endostatin variations in childhood acute lymphoblastic leukaemia--comparison with basic fibroblast growth factor and vascular endothelial growth factor. Leuk Res; 2007 May;31(5):629-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endostatin variations in childhood acute lymphoblastic leukaemia--comparison with basic fibroblast growth factor and vascular endothelial growth factor.
  • Angiogenic factors such as basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) were previously studied in childhood acute lymphoblastic leukaemia (ALL) but little is known concerning the anti-angiogenic response in ALL.
  • At diagnosis, the plasma levels of the anti-angiogenic factor endostatin were significantly higher in 33 children with ALL than in controls (median values 17.7 and 7.6 ng/ml, respectively, p=0.0192) but no relationship was observed with plasma bFGF or VEGF levels.
  • In addition, endostatin levels remained elevated in remission, suggesting that endostatin could have a stromal origin as well.
  • [MeSH-major] Endostatins / metabolism. Fibroblast Growth Factor 2 / metabolism. Neoplasm Recurrence, Local / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Blotting, Western. Case-Control Studies. Cell Proliferation. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Hepatomegaly. Humans. Immunoenzyme Techniques. Immunophenotyping. Infant. Lymphocytes / metabolism. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011029.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endostatins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


6. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet; 2005 Aug 20-26;366(9486):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
  • BACKGROUND: The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia could be improved by allogeneic haemopoietic cell transplantation.
  • We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission.
  • Very-high-risk acute lymphoblastic leukaemia in first complete remission was defined by the presence of at least one of the following criteria:.
  • (1) failure to achieve complete remission after the first four-drug induction phase;.
  • INTERPRETATION: Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous


7. Malik M, Gürcan HM, Ahmed AR: Coexistence of mucous membrane pemphigoid and connective-tissue disease. Clin Exp Dermatol; 2010 Mar;35(2):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of reporting, the MMP was in a prolonged sustained remission in all eight patients.

  • MedlinePlus Health Information. consumer health - Connective Tissue Disorders.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438545.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


8. Yoruk A, Erguven M, Celiker E, Aki H, Timur C, Yuksel E, Ozkan H: Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass. Pediatr Hematol Oncol; 2008 Apr-May;25(3):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass.
  • Spontaneous remission/regression of cancer is defined as partial or complete disappearance of malignant disease temporarily or permanently in the absence of medical treatment.
  • This event is named as spontaneous regression for solid tumors and spontaneous remission for leukemia.
  • The authors report the case of a girl aged 4 years and 3 months, who presented with mediastinal mass and leukemic findings in the bone marrow both of which reappeared after spontaneous regression and remission, respectively.
  • [MeSH-major] Mediastinal Neoplasms. Neoplasm Regression, Spontaneous. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432500.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Bhatti FA, Hussain I, Ali MZ: Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature. J Hematol Oncol; 2009;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature.
  • Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the peripheral blood and bone marrow.
  • We describe a rare presentation of acute lymphoblastic leukemia, in a young adult male who had vague and minimal symptoms with mild splenomegaly.
  • The blasts were positive for common precursor B cell markers on flow cytometry.
  • The patient had a unique cytogenetic abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia.
  • He was categorized as poor risk due to failure to achieve complete remission after induction with UK ALL XII chemotherapy.
  • [MeSH-major] Eosinophilia / complications. Eosinophilia / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Dev Pathol. 2003 Nov-Dec;6(6):558-63 [15018456.001]
  • [Cites] Blood. 1973 Sep;42(3):377-84 [4516523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):382-90 [3546615.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):25-31 [3478077.001]
  • [Cites] Acta Haematol. 1989;82(2):85-90 [2508400.001]
  • [Cites] Blood. 1990 Jul 15;76(2):285-9 [2114933.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):151-5 [1388044.001]
  • [Cites] Blood. 1996 May 1;87(9):3579-86 [8611680.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2459-63 [8630411.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):287-95 [9031109.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2036-41 [9058725.001]
  • [Cites] N Engl J Med. 1998 May 28;338(22):1592-600 [9603798.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3038-45 [15284118.001]
  • [Cites] Lab Hematol. 2008;14(1):7-9 [18403314.001]
  • [Cites] Chin Med J (Engl). 2008 Sep 5;121(17):1744-6 [19024110.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):906-15 [10702799.001]
  • [Cites] Ann Hematol. 2000 May;79(5):272-4 [10870483.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1050-5 [11159536.001]
  • [Cites] Leukemia. 2001 Jun;15(6):915-20 [11417477.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):191-200 [12939747.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):955-6 [14632791.001]
  • [Cites] Pediatr Dermatol. 2003 Nov-Dec;20(6):502-5 [14651570.001]
  • (PMID = 19545391.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  • [Other-IDs] NLM/ PMC2706857
  •  go-up   go-down


10. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet; 2010 Dec 11;376(9757):2009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
  • BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static.
  • We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.
  • Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype.
  • INTERPRETATION: As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation.
  • FUNDING: Cancer Research UK, Leukaemia and Lymphoma Research, Cancer Council NSW, and Sporting Chance Cancer Foundation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / therapeutic use. Mitoxantrone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] J Cell Mol Med. 2009 Oct;13(10):4239-56 [19725919.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2339-47 [20385996.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Leukemia. 2010 Feb;24(2):450-9 [20016529.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):648-54 [19841326.001]
  • [Cites] Cell Mol Immunol. 2009 Dec;6(6):469-75 [20003823.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):453-8 [18928659.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62 [14504921.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18814-23 [14963025.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6 [15494596.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Int J Hematol. 1991 Jun;54(3):219-30 [1747457.001]
  • [Cites] Haematologica. 1997 Nov-Dec;82(6):664-7 [9499665.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Clin Exp Immunol. 2005 Jan;139(1):152-8 [15606626.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 [15647217.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1968-70 [21131040.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Mar;8(3):123 [21480558.001]
  • (PMID = 21131038.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7D96IR0PPM / pegaspargase; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC3010035
  •  go-up   go-down


11. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B: Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant; 2006 Jan;12(1):102-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
  • Acute graft-versus-host disease (GVHD) was limited to grade I to II, whereas chronic graft-versus-host disease occurred in 9 patients, mostly (n = 7) with limited disease.
  • Molecular relapses (8 chronic myeloid leukemia [CML] and 1 non-Hodgkin lymphoma) that occurred not earlier than the sixth month after transplantation were treated with donor lymphocyte infusion (DLI), which induced complete remission in all but 1 CML patient with persistent very low BCR-ABL molecular levels.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Leukocyte Reduction Procedures. Peripheral Blood Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399574.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


12. Rowe JM: Optimal management of adults with ALL. Br J Haematol; 2009 Feb;144(4):468-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.
  • Over 80% of adults can achieve a complete remission; however, the majority of such patients relapse.
  • Prognostic factors have been more clearly defined, moving cytogenetics and molecular determinants forefront, much like acute myeloid leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Humans. Neoplasm, Residual. Prognosis. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055668.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


13. Ziegler DS, Dalla Pozza L, Waters KD, Marshall GM: Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy. Med J Aust; 2005 Jan 17;182(2):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy.
  • In most cases, childhood leukaemia has a fetal origin, but multiple molecular events are required after birth for pre-leukaemic cells to progress to leukaemia.
  • Cure rates for acute lymphoblastic leukaemia (ALL) now approach 80%.
  • A high level of minimal residual disease detected by polymerase chain reaction in patients with ALL in remission has profound prognostic importance and is the focus of a major Australian study attempting to prevent relapse in these children.
  • [MeSH-major] Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / adverse effects. Child. Cranial Irradiation / adverse effects. Humans. Leukemia / diagnosis. Leukemia / physiopathology. Leukemia / therapy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651967.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 45
  •  go-up   go-down


14. Rana ZA, Rabbani MW, Sheikh MA, Khan AA: Outcome of childhood acute lymphoblastic leukaemia after induction therapy--3 years experience at a single paediatric oncology centre. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood acute lymphoblastic leukaemia after induction therapy--3 years experience at a single paediatric oncology centre.
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy.
  • It represents 25% of all childhood cancers and approximately 75% of all cases of childhood leukaemia.
  • Objective was to see the bone marrow remission pattern at the end of induction therapy in paediatric ALL patients in our setup.
  • Diagnosis was based on history, examination, blast cells count on peripheral blood film and bone marrow biopsy and immunophenotyping on peripheral blood/bone marrow aspirate.
  • Bone marrow biopsy was repeated at day 28 of induction therapy and remission pattern was seen.
  • At day 28 of induction therapy, 28 (74%) patients went into complete remission (< 5% blast cells in bone marrow), 2 (5%) into partial remission (5-25% blast cells in bone marrow) and 1 (3%) was not in remission (> 25% blast cells in the bone marrow).
  • Remission can be achieved in most of these patients after induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Clinical Protocols. Female. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067050.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


15. Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF: WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood; 2010 Jun 24;115(25):5222-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.
  • The impact of WT1 mutations in acute myeloid leukemia (AML) is not completely settled.
  • We aimed to determine the clinical implication of WT1 mutation in 470 de novo non-M3 AML patients and its stability during the clinical course.
  • WT1 mutations disappeared at complete remission in all WT1-mutated patients studied.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Mutation. WT1 Proteins / genetics


16. Konn ZJ, Martineau M, Bown N, Richards S, Swansbury J, Talley P, Wright SL, Harrison CJ: Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2010 Mar;49(3):253-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia.
  • This study describes the cytogenetics of 33 children with ETV6-RUNX1 positive acute lymphoblastic leukemia (ALL) who had been in continuous complete remission for a minimum of 8.8 years [median event-free survival (EFS) 10.9 years].
  • Interphase fluorescence in situ hybridization (FISH) at diagnosis showed deletion of the second ETV6 signal from all fusion positive cells in 45% of the long-term survivors but in none of the relapsed patients, whereas patients with mixed populations with retained or lost second signals were more frequent among those who had relapsed (69%) than the long-term survivors (21%).
  • It appears that the two groups have some distinguishing cytogenetic features at the time of diagnosis, which may provide pointers to relapse that are worthy of more detailed study.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Fusion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998443.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


17. Fadilah SA, Goh KY: Breast and ovarian recurrence of acute lymphoblastic leukaemia after allogeneic peripheral blood haematopoietic stem cell transplantation. Singapore Med J; 2009 Dec;50(12):e407-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast and ovarian recurrence of acute lymphoblastic leukaemia after allogeneic peripheral blood haematopoietic stem cell transplantation.
  • Breast recurrence of acute lymphoblastic leukaemia (ALL) after stem cell transplant is uncommon, with less than 20 reported cases in the literature.
  • We describe the first case of simultaneous bilateral breast and ovarian relapses after allografting in ALL, occurring in an 18-year-old female Chinese patient while she was having oral and hepatic chronic GvHD, persistent haematological remission and donor haematopoiesis.
  • This case suggests that there may be different mechanisms for bone marrow vs. extramedullary relapses and a complex relationship between GvHD and graft-versus-leukaemia.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / secondary. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087541.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


18. Leszczyńska E, Ostrowska H, Krawczuk-Rybak M: [Plasma proteasome 20S activity in children treated for acute lymphoblastic leukaemia]. Med Wieku Rozwoj; 2007 Jan-Mar;11(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma proteasome 20S activity in children treated for acute lymphoblastic leukaemia].
  • THE AIM of our study was: to determine the proteasome 20S activity in plasma of patients treated for acute lymphoblastic leukaemia.
  • METHODS: Plasma proteasome activity was measured in children (n=16) at two points: at diagnosis and on the 33rd day using the spectrophotometric method with peptidic substrate and selective proteasome activator 0.03% SDS.
  • RESULTS: 1. At diagnosis we observed high activity of the proteasome 20S in comparison to control (p<0.005).
  • After haematological remission the proteasome 20S activity lowered by about 50% (p<0.05).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proteasome Endopeptidase Complex / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965462.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


19. Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM: HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant; 2007 Aug;40(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
  • To examine relapse, survival and transplant-related complications in relationship to disease- and pre-treatment-related characteristics, we evaluated 132 children, who consecutively received an allogeneic HLA-identical SCT for acute leukaemia in our centre: ALL in first remission (n=24), ALL in second remission (n=53) and AML in first remission (n=55).
  • The incidence of acute GVHD was 17%; 6% was grades II-IV.
  • AML patients with acute GVHD got no relapse (P=0.02); this was not the case in ALL patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572715.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Kawabata Y, Hirokawa M, Saitoh Y, Kosugi S, Yoshioka T, Fujishima M, Fujishima N, Kameoka Y, Saitoh H, Kume M, Takahashi N, Sawada K: Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia. Int J Hematol; 2006 Dec;84(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.
  • A 43-year-old Japanese woman underwent unrelated cord blood transplantation (CBT) during remission for acute lymphoblastic leukemia with t(4; 11)(q21;q23).
  • The posttransplantation clinical course was mostly uneventful, and the leukemia remained in remission.
  • [MeSH-major] Epstein-Barr Virus Infections. Hemorrhage. Herpesvirus 4, Human. Lymphohistiocytosis, Hemophagocytic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


21. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V, Medical Research Council Childhood Leukaemia Working Party: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol; 2005 Apr;129(1):35-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
  • We report on the outcome of children with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL) treated on the UK Medical Research Council (MRC) trial for childhood ALL, MRC ALL 97, between January 1997 and June 2002.
  • Thirty-six (86%) achieved first complete remission (CR1) at the end of induction, of which 28 underwent BM transplantation (BMT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801953.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


22. Zhang J, Mi YC, Wang Y, Lin D, Li W, Sun XM, Zhou K, Bian SG, Wang JX: [Study on the clinical characteristics of adult biphenotypic acute leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):18-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the clinical characteristics of adult biphenotypic acute leukaemia].
  • OBJECTIVE: To analyze the clinical and biological characteristics and prognosis of adult biphenotypic acute leukaemia (BAL).
  • The chemotherapy regimens were accordingly for acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) or for both ALL and AML.
  • (1) The incidence of BAL in acute leukaemias was 6.7%, with a male predominance and 52.3% of BAL patients had WBC > or = 30 x 10(9)/L and 16.9% WBC > or = 100 x 10(9)/L. (2) Percentages of coexpression of myeloid and B lymphoid antigens were 81.5%, of myeloid and T lymphoid antigens 10.8%, of myeloid, B- and T lymphoid antigens 4.6%, and of B and T lymphoid antigens 3.1%. (3) Normal and abnormal karyotypes accounted for 41.5% and 58.5%, respectively in 53 BAL patients with karyotype analysis.
  • The rate of Ph (+) or bcr-abl (+) was 32.1%. (4) 31 (56.4%) of 65 patients achieved complete remission (CR), but CR rate was only 35.3% for Ph (+) or bcr-abl (+) cases. CONCLUSION:.
  • (1) High white blood cell count and coexpression of myeloid/B lymphoid antigens are common in BAL. (2) Abnormal karyotypes and Ph (+) or bcr-abl( +) often happen. (3) The treatment outcome of BAL is poor.
  • [MeSH-major] Leukemia, Biphenotypic, Acute

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563029.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Hato A, Murayama T, Nishikawa S, Kajimoto K, Gomyo H, Sugimoto T, Mizuno I, Koizumi T: Philadelphia chromosome positive acute lymphoblastic leukemia showing normal karyotype in G-banding chromosomal examination before chemotherapy. Hematology; 2005 Oct;10(5):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome positive acute lymphoblastic leukemia showing normal karyotype in G-banding chromosomal examination before chemotherapy.
  • A diagnosis of acute lymphoblastic leukaemia was made on the basis of a 61.6% infiltration of leukemic cells in his bone marrow.
  • He received combination chemotherapy, and achieved hematological complete remission.
  • At the initial diagnosis, Ph chromosome was not detected because the G-banding method analyzed only metaphase cells, which contained few Ph-positive clones.
  • [MeSH-major] Bone Marrow / pathology. Leukemic Infiltration / pathology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273725.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Knapper S: FLT3 inhibition in acute myeloid leukaemia. Br J Haematol; 2007 Sep;138(6):687-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 inhibition in acute myeloid leukaemia.
  • Activating mutations of FLT3 are present in approximately one-third of acute myeloid leukaemia patients and are associated with adverse clinical outcome, while many non-mutated cases also show evidence of FLT3 activation.
  • FLT3 inhibition may also be effective used in combination with other molecularly targeted agents, in postchemotherapy stem-cell-directed maintenance therapy and in MLL-rearranged infant acute lymphoblastic leukaemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17655729.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HSP90 Heat-Shock Proteins; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 89
  •  go-up   go-down


25. De A, Menell JS: Isolated renal relapse in acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Mar;32(2):150-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse in acute lymphoblastic leukemia.
  • Current therapy for acute lymphoblastic leukemia have resulted in cure rates over 80%.
  • We report the unusual case of a young man who presented with an isolated kidney relapse after maintaining remission from acute lymphoblastic leukemia for over 6 years.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048689.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N: A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol; 2009 Dec;147(5):691-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).
  • Sirolimus has been shown to have activity against human acute lymphoblastic leukaemia at serum levels used for immunosuppression.
  • The study cohort included 18 patients in high-risk (HR) first complete remission (CR1), 16 in HR CR2, 17 in intermediate risk (IR) CR2, and 12 in CR3+.
  • Cumulative incidence of acute GVHD grade II-IV and III-IV was 38% and 21% respectively, while the cumulative incidence of chronic GVHD was 32%.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1112-5 [17473063.001]
  • [Cites] Eur J Clin Invest. 2008 Jan;38(1):43-52 [18173550.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):66-70 [18307022.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):531-7 [18410895.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S39-42 [18545243.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6 [18640576.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4425-31 [18776081.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5767-74 [19001324.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):62-71 [19147081.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6A):3801-8 [19189667.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Blood. 2002 May 1;99(9):3151-7 [11964277.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Dec;24(9):746-50 [12468917.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2043-8 [12406916.001]
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] Blood. 2003 May 15;101(10):3835-9 [12732501.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1601-5 [12730113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):471-6 [15273708.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7 [15983555.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5 [16041306.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1396-404 [16219577.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • (PMID = 19744131.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116660-04; United States / NCI NIH HHS / CA / R01 CA116660; United States / NCI NIH HHS / CA / CA116660-04; United States / NCI NIH HHS / CA / R01 CA102646; United States / NCI NIH HHS / CA / R01 CA102646-05; United States / NCI NIH HHS / CA / CA102646-05; United States / NCI NIH HHS / CA / CA102646; United States / NCI NIH HHS / CA / CA1116660
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS209799; NLM/ PMC2888481
  •  go-up   go-down


27. Gubar' EE, Bochkova AG, Bunchuk NV: [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis]. Ter Arkh; 2008;80(5):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A MTX dose was gradually increased from 7.5 mg/week to 17.5 mg/week in an attempt to achieve remission in all the patients.
  • [MeSH-minor] Adult. Aged. Arthralgia / drug therapy. Arthralgia / etiology. Dose-Response Relationship, Drug. Drug Therapy, Combination. Drug Tolerance. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pain Measurement. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. SULFASALAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590110.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 3XC8GUZ6CB / Sulfasalazine; 4QWG6N8QKH / Hydroxychloroquine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Rajić Z, Colović N, Sretenović M, Plecić M, Janković S, Bakrac M, Colović M: [Hepatosplenic candidiasis in acute leukaemia patients]. Srp Arh Celok Lek; 2008 Jul-Aug;136(7-8):414-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic candidiasis in acute leukaemia patients].
  • INTRODUCTION: Hepatosplenic candidiasis is a disseminated invasive fungal infection that may affects patients with acute leukaemia.
  • CASE OUTLINE: The authors present three patients, two women and one men, aged 23, 26 and 33 years, with acute leukaemia; one with acute myeloblastic and two with acute lymphoblastic leukaemia who developed hepatosplenic candidiasis.
  • The diagnosis was based on prolonged fever, elevated serum bilirubin and alkaline phosphatase, as well as characteristic lesions on computed tomography, nuclear magnetic resonance and ultrasonographic findings and positive blood culture in one patient.
  • Two patients died due to progression of leukaemia.
  • CONCLUSION: If leukaemia patient in remission after chemotherapy develops a prolonged fever of unknown origin, hepatosplenic candidiasis has to be considered and all efforts should be done to diagnose it.
  • The diagnosis is based on clinical presentation and imaging techniques.
  • [MeSH-major] Candidiasis / complications. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Liver Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / complications


29. Polat M, Lenk N, Kürekçi E, Oztaş P, Artüz F, Alli N: Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug. Am J Clin Dermatol; 2007;8(6):389-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug.
  • We describe a 5-year-old boy with acute lymphoblastic leukemia in remission, in whom CBDC developed after treatment with trimethoprim/sulfamethoxazole (cotrimoxazole).
  • [MeSH-major] Anti-Infective Agents / adverse effects. Drug Eruptions / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Skin Diseases, Vesiculobullous / chemically induced. Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects


30. Daniel SV, Vani DH, Smith AM, Hill QA, Menon KV: Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult. JOP; 2010;11(1):72-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult.
  • CONTEXT: To highlight a rare presentation of acute lymphoblastic leukaemia.
  • Four weeks after presenting, the white cell count became elevated with blasts on the blood film and bone marrow biopsy revealed a precursor B cell acute lymphoblastic leukaemia.
  • After induction chemotherapy his jaundice resolved, the pancreatic mass reduced in size and he is now in a complete remission.
  • CONCLUSION: Acute lymphoblastic leukaemia may mimic common causes of a pancreatic mass such as adenocarcinoma and should be considered as part of the differential diagnosis when atypical features are present.
  • [MeSH-major] Jaundice, Obstructive / diagnosis. Pancreatic Diseases / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Organ Size. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065559.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Ross A, McLean TW, Farber R, Weaver RG Jr, Chauvenet A, Givner LB, Shetty AK: Retinitis following varicella in a vaccinated child with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Aug;45(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinitis following varicella in a vaccinated child with acute lymphoblastic leukemia.
  • We report a 7-year-old patient with T-cell acute lymphoblastic leukemia in remission who presented with visual complaints 2 weeks after developing chickenpox.
  • Ophthalmologic evaluation revealed acute retinitis in the right eye.
  • Early diagnosis of VZV retinopathy and aggressive antiviral treatment is critical to prevent acute and long-term ocular sequelae.
  • [MeSH-major] Chickenpox / complications. Leukemia, T-Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Retinitis / virology
  • [MeSH-minor] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Chickenpox Vaccine / immunology. Child. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2007 Jun 15;48(7):716 [16607647.001]
  • (PMID = 15880424.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Chickenpox Vaccine; X4HES1O11F / Acyclovir
  • [Number-of-references] 33
  •  go-up   go-down


32. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK: Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol; 2010 Nov;151(4):295-311
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
  • Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years.
  • Despite this success, a significant subset of paediatric leukaemia patients either relapse or fail to ever achieve a complete remission.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Molecular Targeted Therapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • [Cites] Pediatr Res. 2005 Mar;57(3):430-7 [15659698.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1545-50 [15746059.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 [15841378.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1049-58 [16038731.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3532-7 [16051737.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):503-14 [16032400.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2662-9 [16675557.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):833-7 [16769825.001]
  • [Cites] Mol Cancer Ther. 2009 Jul;8(7):1808-17 [19567821.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):505-8 [19418547.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):978-83 [19637330.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2678-87 [19643988.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1243-6 [19838194.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):401-12 [19878872.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5459-68 [19826124.001]
  • [Cites] Blood. 2007 Jul 15;110(2):678-85 [17395781.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1269-82 [17613754.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1500-9 [17499001.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2774-5 [17881645.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9490-500 [17909059.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1639-48 [18347165.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5271-8 [19843886.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5490-8 [19855078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7 [20018760.001]
  • [Cites] Nat Med. 2010 Feb;16(2):205-13 [20072130.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2010 Jul 1;115(26):5312-21 [20139093.001]
  • [Cites] Bioconjug Chem. 2009 Aug 19;20(8):1587-94 [19572629.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):134-42 [1998499.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leuk Res. 1992 Jun-Jul;16(6-7):597-605 [1635378.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2826-34 [1280479.001]
  • [Cites] Clin Exp Immunol. 1992 Dec;90(3):368-75 [1281055.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1025-31 [8427984.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24057-66 [11929866.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1173-82 [12390251.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8173-7 [12444553.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Blood. 2003 Jul 1;102(1):269-75 [12623837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7638-43 [12794186.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1824-32 [12738674.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4483-93 [14555522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4268-75 [14976048.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Nature. 1984 Aug 16-22;310(5978):583-6 [6087162.001]
  • [Cites] Science. 1987 Jan 2;235(4784):85-8 [3541203.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):631-5 [3543692.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14701-4 [2203759.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18141-4 [10373409.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Adv Exp Med Biol. 1999;457:325-33 [10500808.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Nat Med. 2005 Jan;11(1):71-6 [15619634.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27084-90 [9765224.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):680-5 [9892693.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):715-22 [10048973.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1181-9 [18085673.001]
  • [Cites] Blood. 2008 May 15;111(10):5093-100 [18349321.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1101-9 [18483299.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18292-302 [18434310.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):909-15 [8164041.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):292-301 [7575604.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):645-8 [8628398.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2589-94 [9000132.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]
  • [Cites] Leukemia. 2000 Mar;14(3):399-402 [10720133.001]
  • [Cites] Blood. 2000 Jul 15;96(2):676-84 [10887134.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Biochemistry. 2001 Jan 30;40(4):1117-23 [11170436.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Cell Death Differ. 2001 Oct;8(10):1014-21 [11598799.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46639-46 [11583996.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):685-99 [16997177.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6092-100 [16652142.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):31-40 [16865529.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):327-33 [17080335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1783-8 [17363533.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1789-93 [17363534.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):985-94 [18615627.001]
  • [Cites] Pathol Oncol Res. 2008 Sep;14(3):275-9 [18575824.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Oncologist. 2008 Nov;13(11):1181-92 [18987046.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):218-21 [18692895.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):886-91 [19455460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Leukemia. 2009 Jul;23(7):1342-3 [19322208.001]
  • (PMID = 20813012.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD000850; United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / R01 CA137078; United States / NCI NIH HHS / CA / 5P50CA058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.- / Phosphotransferases
  • [Other-IDs] NLM/ NIHMS374428; NLM/ PMC3354740
  •  go-up   go-down


33. Li CK, Chik KW, Ha SY, Lee AC, Yuen HL, Ling SC, Lee V, Chan GC, Shing MM, Chan LC, Ng MH: Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study. Hong Kong Med J; 2006 Feb;12(1):33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study.
  • OBJECTIVE: To study the outcome of children with acute lymphoblastic leukaemia who were treated using a protocol including one or two delayed intensifications.
  • PATIENTS: Children aged between 1 and 17.9 years with newly diagnosed acute lymphoblastic leukaemia seen from November 1997 to December 2002.
  • INTERVENTION: Chemotherapy was modified from a German Berlin-Frankfurt-Muenster 95 (BFM95) protocol that included a delayed intensification similar to the induction phase repeated 5 months after diagnosis.
  • RESULTS: A total of 171 patients were recruited with a median age at diagnosis of 5.57 years (range, 1.15-17.85 years).
  • The induction remission rate was 95.3% and non-leukaemia mortality during remission was 2.3%.
  • CONCLUSION: A more intensive delayed consolidation phase improved the outcome for children with acute lymphoblastic leukaemia by reducing relapses at 4 years.
  • The early treatment complications were manageable and non-leukaemia mortality during remission remained low.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495587.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


34. Marks DI, Aversa F, Lazarus HM: Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant; 2006 Oct;38(7):467-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options.
  • Myeloablative sibling-matched allogeneic transplantation for adult acute lymphoblastic leukaemia provides the best outcome, but most patients lack a suitable, related histocompatible donor.
  • Matched unrelated donor allografts most often are performed in Philadelphia chromosome-positive disease and in second complete remission (CR2); a nearly 30% event-free survival (EFS) can be anticipated in select patients.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Haplotypes. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Graft Survival. Graft vs Host Disease. Humans. Philadelphia Chromosome. Recurrence. Remission Induction. Siblings. Transplantation Conditioning. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892073.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


35. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


36. Wang W, Wang XQ, Xu XP, Lin GW: Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group. J Int Med Res; 2010 Mar-Apr;38(2):432-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
  • This study was designed to evaluate the prevalence of fms-like tyrosine kinase-3 (FLT3) gene mutations in the World Health Organization classified subtypes of acute leukaemia (AL), and their prognostic significance in terms of complete remission (CR), leukaemia-free survival (LFS) and overall survival (OS).
  • Of 468 patients, 374 (79.9%) had acute myeloid leukaemia (AML) and 83 (17.7%) had acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515557.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


37. Lazić J, Dokmanović L, Krstovski N, Predojević J, Tosić N, Pavlović S, Janić D: [Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia]. Srp Arh Celok Lek; 2009 Jul-Aug;137(7-8):384-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia].
  • INTRODUCTION: Acute lymphoblastic leukaemia (ALL) is a malignant clonal disease, one of the most common malignancies in childhood.
  • Contemporary protocols ensure high remission rate and long term free survival.
  • METHODS: Forty-one children with ALL were enrolled in the study group, with initial diagnosis of IgH and TCR gene rearrangements by polimerase chain reaction (PCR).
  • MRD follow-up was performed in induction phase when morphological remission was expected, and after intensive chemiotherapy.
  • RESULTS: In the study group IgH rearrangement was detected in 82.9% of children at the diagnosis, while TCR rearrangement was seen in 56.1%.
  • [MeSH-major] Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764592.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


38. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R: Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol; 2006 Oct;77(4):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
  • The treatment of relapsed adult acute lymphoblastic leukaemia (ALL) is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of multidrug resistance (MDR)-related proteins.
  • Twenty pts (80%) achieved a complete remission (CR) and two (8%) entered a partial remission (PR) for an overall response (OR) rate of 88% (22/25), with a tolerable toxicity and without significant cardiotoxicity.
  • Before the start of DNX therapy, 18/25 (72%) cases overexpressed at least one MDR-related protein compared with 9/25 (36%) cases with MDR overexpression at diagnosis (P = 0.01).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856922.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Liposomes; 0 / Multidrug Resistance-Associated Proteins; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


39. Li A, Goldwasser MA, Zhou J, Armstrong SA, Wang H, Dalton V, Fletcher JA, Sallan SE, Silverman LB, Gribben JG: Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol; 2005 Oct;131(2):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.
  • Infant acute lymphoblastic leukaemia (ALL) represents a rare but unique subset with poor prognosis.
  • We analysed mixed-lineage leukaemia (MLL) gene rearrangements and the sequences of complete and incomplete immunoglobulin heavy chain gene rearrangements (IGH) in 14 infants (age < or = 12 months at diagnosis) enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Genes, Immunoglobulin. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cytogenetics. Gene Expression. Humans. Infant. Neoplasm, Residual / genetics. Prospective Studies. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197448.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA68484
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Brummel B, Bernbeck B, Schneider DT: Complicated but successful treatment of a patient with ataxia telangiectasia and pre-B-acute lymphoblastic leukemia. Klin Padiatr; 2010 Nov;222(6):391-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complicated but successful treatment of a patient with ataxia telangiectasia and pre-B-acute lymphoblastic leukemia.
  • Pediatric patients may develop lymphomas and acute lymphoblastic leukaemia (ALL), especially of the T-lineage.
  • Over 1 year after the end of the maintenance therapy the patient is still in complete first remission.
  • CONCLUSION: A general recommendation for dose modification in these patients group cannot be made due to the low number of patients suffering from AT and leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ataxia Telangiectasia / diagnosis. Ataxia Telangiectasia / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Remission Induction


41. Kaćanski N, Konstantinidis N, Kolarović J, Slavković B, Vujić D: [Biphenotypic acute leukaemia: case reports of two paediatric patients]. Med Pregl; 2010 Nov-Dec;63(11-12):867-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia: case reports of two paediatric patients].
  • INTRODUCTION: Biphenotypic acute leukaemia is an uncommon type of leukaemia whose blasts co-express myeloid and B-or T-lymphoid antigens.
  • CASE REPORT: We describe two cases of paediatric patients with biphenotypic acute leukaemia.
  • A four-year-old female patient was found to have myeloid and B-lymphoid associated antigens in the same blast cells.
  • She was treated with combined acute myeloid leukaemia/acute lymphoblastic leukaemia induction therapy followed by autologous stem cell transplantation.
  • Another patient was a 20-month-old girl with myeloid and T-lymphoid associated antigens in the blast cells and with normal karyotype.
  • She received acute myeloid leukaemia induction therapy.
  • She has never achieved remission.
  • DISCUSSION: Immunophenotype is essential to establish the diagnosis of biphenotypic acute leukaemia according to the scoring system adopted by the European Group of Immunological Classification of Leukaemia.
  • There is no agreement about uniformity in treatment for the patients with this type of leukaemia.
  • Biphenotypic acute leukaemia is a high risk leukaemia which requires a more intensive treatment.
  • CONCLUSION: Therapy for every patient with biphenotypic acute leukaemia should depend on their immunophenotype and gene rearrangement profiles.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21553470.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


42. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH: Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev; 2005 Nov;19(6):289-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
  • Acute lymphoblastic leukaemia (ALL) responds well to chemotherapy and the majority of children and a significant proportion of adults are cured of their disease after primary therapy.
  • The infusion of unmodified donor lymphocytes (DLI) following relapse after allogeneic transplantation has been shown to be curative in patients with chronic myeloid leukaemia (CML).
  • For example, some strategies utilise the patients dendritic cells (DC) to present tumour antigens to donor lymphocytes and convert them into CTL either by pulsing DC taken in remission with ALL cells or lysate, fusing such 'normal' DC with ALL cells or using DC cultured from the patient's ALL cells.
  • Other approaches include exploiting the expression of leukaemia-specific antigens such as the proteinase PR-3 or the zinc finger transcription factor Wilms tumour-1 protein (WT-1) to stimulate CTL responses.
  • [MeSH-major] Immunotherapy, Adoptive. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Child. Child, Preschool. Dendritic Cells / immunology. Dendritic Cells / transplantation. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Neoplasm Proteins / immunology. Secondary Prevention. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / transplantation. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275419.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 89
  •  go-up   go-down


43. Mele G, Pinna S, Melpignano A, Romano A, Brocca MC, Coppi MR, Quarta G: What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? Leuk Res; 2007 Oct;31(10):1445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of an elderly patient affected by Philadelphia positive Acute Lymphoblastic Leukaemia (Ph(+) ALL) who developed meningeal leukaemia during imatinib monotherapy, despite bone marrow molecular remission.
  • In view of the inefficacy of imatinib at preventing meningeal leukaemia for its poor penetration into the CNS, CNS prophylactic therapy should always be an integral part of any imatinib-based treatment strategy for Ph(+) ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Meningeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Salvage Therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462730.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB: Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood; 2007 Nov 15;110(10):3552-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
  • Although imatinib is clearly the treatment of choice for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment, and the possibility of cure in this disorder.
  • To address these questions, 5 patients with FIP1L1/PDGFRA-positive CEL with documented clinical, hematologic, and molecular remission on imatinib (400 mg daily) and without evidence of cardiac involvement were enrolled in a dose de-escalation trial.
  • All 5 patients who underwent dose de-escalation, but neither of the control patients, experienced molecular relapse (P < .05).
  • Reinitiation of therapy at the prior effective dose led to molecular remission in all 5 patients, although 2 patients subsequently required increased dosing to maintain remission.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Benzamides. Biomarkers, Pharmacological / analysis. Biopsy. Chronic Disease. Dose-Response Relationship, Drug. Eosinophils / cytology. Eosinophils / drug effects. Humans. Imatinib Mesylate. Leukocyte Count. Male. Middle Aged. Recurrence. Remission Induction

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 May 15;99(10):3792-800 [11986238.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4701-7 [12576334.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1423-32 [14534335.001]
  • [Cites] Haematologica. 2003 Oct;88(10):1117-22 [14555307.001]
  • [Cites] Blood. 2004 Jan 15;103(2):473-8 [14504092.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S71-3 [15036945.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2204-5 [15377577.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2093-8 [15345592.001]
  • [Cites] Haematologica. 2005 Jul;90(7):979-81 [15996937.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):286-92 [16409293.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):965-70 [16406016.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Jpn J Clin Oncol. 2006 Nov;36(11):704-11 [17068083.001]
  • [Cites] Blood. 2007 Jan 1;109(1):58-60 [16973963.001]
  • [Cites] Leukemia. 2007 Mar;21(3):489-93 [17252009.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:87-112 [11722980.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • (PMID = 17709602.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00044304
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Pharmacological; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / FIP1L1-PDGFRA fusion protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC2077306
  •  go-up   go-down


45. Capouya JD, Berman DM, Dumois JA: Mollaret's meningitis due to human herpesvirus 6 in an adolescent. Clin Pediatr (Phila); 2006 Nov;45(9):861-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the first pediatric case of Mollaret meningitis in an adolescent female with acute lymphoblastic leukemia in remission.

  • Hazardous Substances Data Bank. Foscarnet .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041177.001).
  • [ISSN] 0009-9228
  • [Journal-full-title] Clinical pediatrics
  • [ISO-abbreviation] Clin Pediatr (Phila)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 364P9RVW4X / Foscarnet
  •  go-up   go-down


46. Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FR: Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood; 2009 Dec 24;114(27):5444-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
  • Fifty-eight patients older than 50 years with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) were treated with (131)I-BC8 Ab and fludarabine plus 2 Gy total body irradiation.
  • Treatment produced a complete remission in all patients, and all had 100% donor-derived CD3(+) and CD33(+) cells in the blood by day 28 after the transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Aged. Antibodies / administration & dosage. Antibodies / immunology. Antigens, CD45 / immunology. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / pharmacokinetics. Male. Middle Aged. Risk Factors. Survival Analysis. Survival Rate. Tissue Distribution. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation


47. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • 19 patients were transplanted in first remission and 42 at a later stage of the disease.
  • RESULTS: At the end of 2006, 26 patients (43%) were alive; 21 (35%) in complete remission and 5 with relapse.
  • Estimated 5-year actuarial leukemia-free survival was 35 %.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • A larger number of patients should be offered such treatment during the first remission than what was the case in the 20-year period this study took place.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


48. Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, Linderholm M, Wahlin A, Linder O, Smedmyr B, Swedish Adult ALL Group: Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant; 2005 Jun;35(12):1141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986.
  • Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse.
  • The 5-year DFS was higher for patients transplanted in first remission 32% (CI 24-40%) compared to 14% (CI 5-23%; P<0.0001) in patients transplanted beyond first remission.
  • Limited chronic graft-versus-host-disease (GVHD) was associated with an improved DFS of 53% (CI 38-69%) compared to no chronic GVHD of 22% (CI 10-36%; P=0.0008), indicating a clinically important graft-versus-leukaemia effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease. Graft vs Leukemia Effect. Humans. Male. Middle Aged. Philadelphia Chromosome. Probability. Recurrence. Retrospective Studies. Sweden. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834433.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, Auquier P, Michel G: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant; 2009 Apr;43(8):637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
  • We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal).
  • The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / physiopathology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Body Height. Child. Female. Growth Disorders / etiology. Humans. Male. Remission Induction. Time Factors. Treatment Outcome. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011662.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S: Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells; 2009 Jun;27(6):1421-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the basis of the promising clinical outcomes in SLE mice, we treated four CTX/glucocorticoid treatment-refractory SLE patients using allogenic MSCT and showed a stable 12-18 months disease remission in all treated patients.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2004 May 1;363(9419):1439-41 [15121408.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Transplantation. 1974 Apr;17(4):331-40 [4150881.001]
  • [Cites] Ciba Found Symp. 1988;136:42-60 [3068016.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10340-4 [7694292.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1447-59 [8666903.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1704-13 [15599395.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1815-22 [15494428.001]
  • [Cites] Immunity. 2005 Mar;22(3):329-41 [15780990.001]
  • [Cites] Curr Opin Rheumatol. 2005 Sep;17(5):518-22 [16093827.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3318-25 [16322775.001]
  • [Cites] Blood. 2006 Jan 1;107(1):367-72 [16141348.001]
  • [Cites] JAMA. 2006 Feb 1;295(5):527-35 [16449618.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1484-90 [16239427.001]
  • [Cites] Springer Semin Immunopathol. 2006 Aug;28(1):3-16 [16838180.001]
  • [Cites] Immunol Cell Biol. 2006 Oct;84(5):413-21 [16869941.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Oct;2(10):562-9 [17016482.001]
  • [Cites] J Autoimmun. 2006 Sep;27(2):110-8 [16890406.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):2832-6 [17051620.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2673-82 [17088434.001]
  • [Cites] Transplantation. 2007 Jan 15;83(1):71-6 [17220794.001]
  • [Cites] Scand J Immunol. 2007 Apr;65(4):336-43 [17386024.001]
  • [Cites] Lupus. 2007;16(2):121-8 [17402368.001]
  • [Cites] Trends Immunol. 2007 May;28(5):219-26 [17400510.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1370-8 [17435112.001]
  • [Cites] Clin Rheumatol. 2007 Dec;26(12):2073-9 [17447103.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Jan;17(1):31-41 [18095917.001]
  • [Cites] Autoimmun Rev. 2008 Jan;7(3):256-61 [18190888.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e2 [18205972.001]
  • [Cites] N Engl J Med. 2008 Feb 28;358(9):929-39 [18305268.001]
  • [Cites] Lupus. 2008 May;17(5):421-5 [18490420.001]
  • [Cites] Immunol Res. 2008;41(1):79-86 [18506645.001]
  • [Cites] Nat Med. 2008 Jul;14(7):748-55 [18542049.001]
  • [Cites] PLoS One. 2008;3(7):e2615 [18612428.001]
  • [Cites] Curr Opin Rheumatol. 2008 Sep;20(5):519-25 [18698171.001]
  • [Cites] Lupus. 2008 Dec;17(12):1064-9 [19029273.001]
  • [Cites] Semin Arthritis Rheum. 2008 Dec;38(3):218-27 [18206214.001]
  • [Cites] Cell Mol Immunol. 2008 Dec;5(6):417-24 [19118507.001]
  • [Cites] Acta Reumatol Port. 2008 Apr-Jun;33(2):157-69 [18604181.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):307-16 [10637244.001]
  • [Cites] N Engl J Med. 2001 Feb 1;344(5):385-6 [11195802.001]
  • [Cites] Exp Hematol. 2002 Jan;30(1):42-8 [11823036.001]
  • [Cites] Nat Biotechnol. 2002 Jun;20(6):587-91 [12042862.001]
  • [Cites] Exp Hematol. 2002 Aug;30(8):870-8 [12160838.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Leukemia. 2003 Feb;17(2):474-6 [12592355.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Cell. 2004 Jul 23;118(2):149-61 [15260986.001]
  • (PMID = 19489103.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE017449; United States / NIDCR NIH HHS / DE / R21 DE017632; United States / NIDCR NIH HHS / DE / R01DE017449; United States / NIDCR NIH HHS / DE / R21 DE017632-01A2; United States / NIDCR NIH HHS / DE / R01 DE017449-03
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies
  • [Other-IDs] NLM/ NIHMS106821; NLM/ PMC2704254
  •  go-up   go-down


51. Howie AJ, Agarwal A, Sebire NJ, Trompeter RS: Glomerular tip changes in childhood minimal change nephropathy. Pediatr Nephrol; 2008 Aug;23(8):1281-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was in remission at follow-up.
  • Three patients were in remission, two on no treatment at follow-up, and one on ciclosporin.
  • The other 44 children were nearly all in remission, 18 without treatment at follow-up, and the rest on various immunosuppressants, but one had persistent proteinuria and multiple segmental lesions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull Johns Hopkins Hosp. 1957 Apr;100(4):173-86 [13426687.001]
  • [Cites] J Pathol. 1995 Oct;177(2):191-9 [7490686.001]
  • [Cites] Nephrol Dial Transplant. 2008 Jan;23(1):186-92 [17704112.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jun;16(6):1163-9 [11390715.001]
  • [Cites] J Pathol. 1986 Sep;150(1):13-20 [3783320.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):987-1001 [15698437.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi33-8 [12953040.001]
  • [Cites] Pediatr Nephrol. 1993 Aug;7(4):370-4 [8398644.001]
  • [Cites] Pediatr Nephrol. 2007 Feb;22(2):215-21 [17146670.001]
  • [Cites] Kidney Int. 1991 Aug;40(2):243-50 [1942772.001]
  • [Cites] Kidney Int. 2006 Mar;69(5):920-6 [16518352.001]
  • [Cites] J Pathol. 2000 Mar;190(4):478-83 [10699998.001]
  • [Cites] Nephrol Dial Transplant. 1993;8(10):1059-63 [8272216.001]
  • [Cites] Nephrol Dial Transplant. 1993;8(7):590-9 [8396741.001]
  • [Cites] J Pathol. 1984 Mar;142(3):205-20 [6707787.001]
  • [Cites] Clin Nephrol. 1987 May;27(5):217-21 [3594937.001]
  • [Cites] Am J Kidney Dis. 2002 Jun;39(6):1168-75 [12046027.001]
  • [Cites] Kidney Int. 2004 May;65(5):1690-702 [15086908.001]
  • [Cites] J Am Soc Nephrol. 2003 Apr;14(4):908-17 [12660325.001]
  • [Cites] Am J Kidney Dis. 2004 Feb;43(2):368-82 [14750104.001]
  • (PMID = 18446377.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 80295-33-6 / Complement C1q
  •  go-up   go-down


52. Proctor SJ, Chapman CE, Sharples R, Lucraft HL, Wilkinson J, Conn J, Middleton PG: Enhanced engraftment of a very low-dose cord blood unit in an adult haemopoietic transplant by addition of six mismatched viable cord units. Stem Cells Int; 2010;2010:431909
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An ablative stem cell transplant was performed in an adult with relapsed acute lymphoblastic leukaemia (ALL), using a single HLA-matched cord blood unit (mononuclear cell dose 0.8 × 10(7)), supported by six mismatched cord blood units (one unit per 10 kg recipient weight).
  • Early molecular remission of ALL was demonstrated using a novel PCR for a mitochondrial DNA mutation in the leukaemic clone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048848.001).
  • [ISSN] 1687-9678
  • [Journal-full-title] Stem cells international
  • [ISO-abbreviation] Stem Cells Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2956468
  •  go-up   go-down


53. Suzuki M, Shimizu T, Kudo T, Shoji H, Ohtsuka Y, Yamashiro Y: Octreotide prevents L-asparaginase-induced pancreatic injury in rats. Exp Hematol; 2008 Feb;36(2):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: L-asparaginase (ASNase) is one of the most effective chemotherapeutic means for inducing remission in acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023522.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Escherichia coli Proteins; 0 / Gastrointestinal Agents; 0 / Trypsin Inhibitors; EC 3.2.1.- / Amylases; EC 3.4.21.4 / Trypsin; EC 3.5.1.1 / Asparaginase; RWM8CCW8GP / Octreotide
  •  go-up   go-down


54. Jurkowska M, Malinowska I, Bal J: [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood]. Przegl Lek; 2005;62(12):1412-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].
  • Current treatment strategies of leukaemia use risk factors existing at the time of diagnosis to establish risk-adapted therapy.
  • This approach currently results in overall 95% rate of complete remission in paediatric acute lymphoblastic leukemia (ALL).
  • This suggests the existence of factors independent from leukaemia genetic background, which influences the outcome of patients with ALL.
  • [MeSH-major] Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786762.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.5.1.18 / Glutathione Transferase
  • [Number-of-references] 33
  •  go-up   go-down


55. Sikorska-Fic B, Stańczak E, Matysiak M, Kamiński A: [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1051-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst].
  • Acute haemorrhagic or necrotizing pancreatitis caused by L-asparaginase is rare but potentially life-threatening complication.
  • We present 2 cases of acute pancreatitis in children aged 2 and 4 years.
  • They were diagnosed to have acute lymphoblastic leukaemia and were treated according to the ALLLIC BFM 2002 protocol.
  • Acute pancreatitis developed in these children after induction therapy and was followed by formation of a pseudocyst.
  • In both cases the diagnosis of this complication was made directly after phase I of the protocol I (after eighth dose of L-Asparaginase).
  • In the first case the course of acute pancreatitis was mild.
  • Normalization of the amylase levels occurred after 7 days and the diagnosis of post inflammatory cyst was made 15 days after the first signs of the disease.
  • In the second case acute pancreatitis had a severe course and the child required treatment in the Intensive Care Unit for 21 days.
  • Currently both children are well and remain in haematological remission and continue maintenance chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Pancreatic Pseudocyst / complications. Pancreatitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Asparaginase / administration & dosage. Asparaginase / adverse effects. Asparaginase / therapeutic use. Child, Preschool. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Drainage. Female. Humans. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531825.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


56. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL: A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl); 2005 Mar;14(1):53-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL).
  • Our goal was to identify and summarize the published literature pertaining to the incidence, prevalence, mortality, aetiology, clinical diagnosis, and management of acute lymphoblastic leukaemia (ALL).
  • Acute lymphoblastic leukaemia represents 12% of all leukaemia cases, with a worldwide incidence projected to be 1-4.75 per 100,000 people.
  • Acute lymphoblastic leukaemia is predominantly a disease of childhood, but it affects adults as well.
  • It accounts for 80% of all leukaemia cases in children.
  • Complete remission rates are high, especially amongst children (even 100%); however, long-term survival at 10 years (event-free survival) is in the range of 63% for children and 25-35% for adults.
  • This implies that there is still a strong need for new therapies to maintain remission and prolong survival.
  • Future treatment strategies may be driven by the patient's minimal residual disease status, a measure that more precisely defines remission, prognosis, responsiveness to therapy, and expected long-term survival.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698386.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


57. Bang UC, Nielsen AM: [The use of adalimumab in severe fistulising Crohn's disease]. Ugeskr Laeger; 2008 Jun 16;170(25):2256
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three patients who received adalimumab, which induced longstanding remission in all three patients.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565318.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; FYS6T7F842 / Adalimumab
  •  go-up   go-down


58. El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK: Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis; 2006 Feb;29(1):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At baseline, bone pain was present in 5 patients and ERT resulted in complete symptomatic remission in all of them.
  • ERT was effective in ameliorating radiological manifestations of skeletal disease and achieving complete remission of bone pain.
  • [MeSH-minor] Adolescent. Bone and Bones / drug effects. Child. Child, Preschool. Egypt. Female. Genotype. Heterozygote. Humans. Infant. Male. Phenotype. Remission Induction. Time Factors


59. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • However, the effect of ALL and of its treatment on body composition in children in remission from ALL has not been fully examined with the use of a reference method.
  • OBJECTIVES: We aimed to determine the body composition and composition of fat-free mass (FFM) in children in remission from ALL.
  • DESIGN: This cross-sectional study measured height, weight, body volume, total body water, and bone mineral content in 24 children in remission from ALL and 24 age-matched, healthy control subjects.
  • Examination of the composition of FFM made it evident that children in remission from ALL had both significantly greater hydration (P = 0.001) and lower density (P = 0.0001) of FFM than did the control children.
  • CONCLUSIONS: Children in remission from ALL may develop excess body fat.
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Absorptiometry, Photon. Body Mass Index. Case-Control Studies. Child. Cross-Sectional Studies. Deuterium. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Models, Biological. Plethysmography. Prednisolone / adverse effects. Prednisolone / therapeutic use. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. DEUTERIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


60. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group: Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol; 2009 Aug;146(3):292-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
  • Detection of minimal residual disease (MRD) after induction and consolidation therapy is highly predictive of outcome for childhood acute lymphoblastic leukaemia (ALL) and is used to identify patients at high risk of relapse in several current clinical trials.
  • To evaluate the prognostic significance of MRD at other treatment phases, MRD was measured by real-time quantitative polymerase chain reaction on a selected group of 108 patients enrolled on the Australian and New Zealand Children's Cancer Study Group Study VII including 36 patients with a bone marrow or central nervous system relapse and 72 matched patients in first remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500099.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ: Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol; 2005 Jul;130(2):233-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
  • Cancer subtype diagnosis using microarray signatures has the potential to transform pathological diagnosis but the routine measurement of genes signatures remains difficult.
  • Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) was used to determine gene signatures.
  • The expression profile of the 17 top-ranked genes distinguishing AML and ALL were measured by RT-PCR in five ALL, 26 AML, 12 AML remission, four chronic myeloid leukaemia (CML) and nine morphologically normal BM samples.
  • Specifically, c-MYB (P </= 0.04) was significantly increased in ALL in the total fraction, whilst HOXA9 (P </= 0.19) and cystatin c (P </= 0.01) were increased in AML in the CD34(+) and CD34(-) fractions, respectively. c-MYB, hSNF2, RBAP48, HKRT-1, LYN, CD33, Adipsin and HOXA9 were increased in AML compared with remission AML, indicating an ability to determine disease activity.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029452.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA, Neoplasm
  •  go-up   go-down


62. Zainal Muttakin AR, Tan AM: Mycobacterium fortuitum catheter-related sepsis in acute leukaemia. Singapore Med J; 2006 Jun;47(6):543-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium fortuitum catheter-related sepsis in acute leukaemia.
  • We report Mycobacterium fortuitum (M. fortuitum) catheter-related sepsis in a five-year-old boy with acute lymphoblastic leukaemia (ALL).
  • The patient was in haematological remission and receiving maintenance chemotherapy via an indwelling central venous catheter (Port-a-Cath).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheters, Indwelling / microbiology. Mycobacterium Infections, Nontuberculous / complications. Mycobacterium fortuitum / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sepsis / etiology
  • [MeSH-minor] Acute Disease. Child, Preschool. Humans. Immunocompromised Host. Male

  • Genetic Alliance. consumer health - Mycobacterium fortuitum.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752025.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A: Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol; 2008 Jun;142(2):227-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
  • The treatment of adults with Philadelphia-negative acute lymphoblastic leukaemia (ALL) depends on the presence of risk factors including age, white blood cell count, immunophenotype and time to complete remission.
  • Patients were treated with a uniform Polish Adult Leukemia Group (PALG) 4-2002 protocol.
  • [MeSH-major] Antigens, CD / analysis. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


64. Sonmez M, Cobanoglu U, Ovali E, Omay SB: Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. J Clin Pharm Ther; 2008 Jun;33(3):329-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Renal Insufficiency / complications. Thiazoles / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Dasatinib. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Male. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452422.001).
  • [ISSN] 1365-2710
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


65. Basara N, Rasche FM, Schwalenberg T, Wickenhauser C, Maier M, Ivovic J, Niederwieser D, Lindner TH: Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? J Transplant; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a case of acute lymphoblastic leukemia in remission presenting a late-onset bilateral hydronephrosis probably due to polyoma BK virus-induced proliferation of bladder endothelium on both ostii.
  • The diagnosis was made virologically by BK virus Polymerase Chain Reaction (PCR) detection in the absence of any other bladder disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936157.001).
  • [ISSN] 2090-0015
  • [Journal-full-title] Journal of transplantation
  • [ISO-abbreviation] J Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2948899
  •  go-up   go-down


66. Mitchell C, Payne J, Wade R, Vora A, Kinsey S, Richards S, Eden T: The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol; 2009 Aug;146(4):424-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.
  • The 1997 acute lymphoblastic leukaemia (ALL) trial (ALL97) was a randomised comparison of prednisolone versus dexamethasone and of 6-mercaptopurine versus 6-thioguanine.
  • There were no significant differences for non-CNS relapse, induction deaths or deaths in remission between the two phases of the trial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / immunology. Immunosuppressive Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549269.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / 98223452
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


67. Kumar R, Nijalingappa S, Grainger J, Ismayl O: Acute disseminated encephalomyelitis mimicking late CNS relapse of acute lymphoblastic leukaemia: case report. J Med Case Rep; 2007;1:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute disseminated encephalomyelitis mimicking late CNS relapse of acute lymphoblastic leukaemia: case report.
  • BACKGROUND: Acute encephalomyelopathy occurring after an allogeneic bone marrow transplant for leukaemia is a diagnostic emergency.
  • The diagnosis can be challenging since there is a wide set of alternative diagnoses, including opportunistic infections and relapse of the leukaemia.
  • CASE PRESENTATION: A 13-year old girl presented with a severe acute myelopathy and encephalopathy.
  • She was in prolonged remission from a central nervous system and bone marrow relapse of an acute lymphoblastic leukaemia, treated with allogeneic bone marrow transplantation.
  • Immunophenotyping and cytogenetic investigations of the girl's cerebrospinal fluid lymphocytosis excluded a late central nervous system relapse of her leukaemia.
  • The diagnosis was acute disseminated encephalomyelitis.
  • CONCLUSION: Acute disseminated encephalomyelitis should be considered in the differential diagnosis of acute encephalomyelopathy after bone marrow transplantation for leukaemia.
  • Demyelinating syndromes such as acute disseminated encephalomyelitis may be late sequelae of bone marrow transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2006 Dec 12;67(11):1990-7 [17159106.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):295-310 [8938302.001]
  • [Cites] Bone Marrow Transplant. 1998 Nov;22(9):873-81 [9827815.001]
  • [Cites] J Neuroimmunol. 1998 Nov 2;91(1-2):19-27 [9846815.001]
  • [Cites] Eur J Paediatr Neurol. 2004;8(5):239-42 [15341905.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1895-904 [12499480.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1994-7 [12499502.001]
  • [Cites] Ann Hematol. 2003 Jan;82(1):37-40 [12574963.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(11):1151-7 [15077130.001]
  • [Cites] Bone Marrow Transplant. 1999 Nov;24(10):1137-40 [10578164.001]
  • (PMID = 17411447.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839762
  •  go-up   go-down


68. Berger C, Le-Gallo B, Donadieu J, Richard O, Devergie A, Galambrun C, Bordigoni P, Vilmer E, Plouvier E, Perel Y, Michel G, Stephan JL: Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant; 2005 May;35(10):991-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia.
  • The purpose of this study was to identify risk factors for hypothyroidism after bone marrow transplantation (BMT) for high-risk or relapsed acute lymphoblastic leukaemia (ALL) in children.
  • In all, 388 children with acute lymphoblastic leukaemia underwent allogeneic bone marrow transplantation between 1984 and 1994.
  • Three factors were significantly associated with the onset of hypothyroidism, namely age, bone marrow transplantation in second remission, and single-dose total body irradiation (TBI).
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Hypothyroidism / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


69. Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, Fink FM, Meister B, Schmitt K, Dieckmann K, Henze G, Haas OA, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol; 2009 Feb;144(4):559-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
  • Relapsed acute lymphoblastic leukaemia (ALL) is the most common cause for a fatal outcome in paediatric oncology.
  • One-hundred-and-seventy-two patients (85%) achieved second complete remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077160.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Ausserer B; Busch U; Müller G; Kurz R; Urban Ch; Berger H; Fink FM; Meister B; Kaulfersch W; Messner H; Mutz I; Stöllinger O; Tulzer W; Schmidt K; Ebetsberger T; Grienberger H; Jones N; Jones R; Rücker J; Haas H; Ploier R; Gadner H; Grümayer-Panzer ER; Krepler P; Mann G; Pichler E; Jürgenssen O; Slavc I; Höcker P; Knapp W; Pickl WF; Haas OA; Lion T; Kärcher KH; Hawlicek R; Pötter R; Dieckmann K
  •  go-up   go-down


70. Bandyopadhyay S, Das D, Das G, Gayen S: Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission. Oman J Ophthalmol; 2010 Sep;3(3):153-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120055.001).
  • [ISSN] 0974-7842
  • [Journal-full-title] Oman journal of ophthalmology
  • [ISO-abbreviation] Oman J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2992166
  •  go-up   go-down


71. Seo P, Specks U, Keogh KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol; 2008 Oct;35(10):2017-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab successfully induced disease remission in all 8 patients.
  • CONCLUSION: Rituximab is an effective therapy for patients with limited WG and may be sufficient to induce sustained remission, even among patients with refractory disease and predominantly necrotizing granulomatous disease manifestations.

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688911.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR052820-01
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


72. Troeger A, Gudowius S, Escherich G, den Boer ML, Glouchkova L, Ackermann B, Meisel R, Laws HJ, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Goebel U, Janka-Schaub GE, Hanenberg H, Dilloo D: High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia. Br J Haematol; 2007 Nov;139(3):450-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
  • In spite of its established role in B-cell function and identification as a prognostically favourable marker in a number of malignancies, little is known about the expression pattern and prognostic significance of p75NTR in B cell precursor-acute lymphoblastic leukaemia (BCP-ALL).
  • p75NTR expression was prospectively studied on primary ALL-blasts in a cohort of paediatric patients with common ALL (n = 86) and preB-ALL (n = 34) treated within the Co-operative study group for childhood acute lymphoblastic leukaemia (CoALL) protocol, CoALL06-97.
  • In patients classified as low-risk at diagnosis, p75NTR expression was significantly higher than in high-risk patients (P = 0.001).
  • Of note, p75NTR expression was lower in the 21 patients who subsequently developed relapse compared with those remaining in remission (P = 0.038).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Nerve Tissue Proteins / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Receptors, Nerve Growth Factor / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910636.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor
  •  go-up   go-down


73. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • METHODS: Patients (1376) up to 18 years of age with first relapse of non-B-cell ALL were treated and achieved a 2nd complete remission (CR).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Germany / epidemiology. Humans. Incidence. Infant. Male. Multicenter Studies as Topic. Remission Induction. Risk Factors. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


74. Ridola V, Buonuomo PS, Maurizi P, Putzulu R, Annunziata ML, Pietrini D, Riccardi R: Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer; 2008 Feb;50(2):378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis.
  • Children suffering from Acute Lymphoblastic Leukaemia (ALL) treated with asparaginase and corticosteroids are at risk of developing severe lipid abnormalities.
  • [MeSH-major] Hypertriglyceridemia / therapy. Plasmapheresis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Combined Modality Therapy. Humans. Leukapheresis. Male. Remission Induction. Triglycerides / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16883590.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triglycerides; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


75. Jarfelt M, Fors H, Lannering B, Bjarnason R: Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2006 Feb;154(2):303-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: Treatment for childhood leukaemia induces many risk factors for development of decreased bone mineral density (BMD).
  • The aim was to study BMD and markers of bone turnover in a well-defined group of survivors of acute lymphoblastic leukaemia (ALL) who had all reached final height as well as peak bone mass, taking both previous treatment and physical activity into consideration.
  • DESIGN: All patients treated for ALL before the onset of puberty in the region of western Sweden, between 1973 and 1985, in first remission were included.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452545.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; 0 / procollagen type I carboxy terminal peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


76. Mantadakis E, Anagnostatou N, Danilatou V, Markaki EA, Spanaki AM, Briassoulis G, Kalmanti M: Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol; 2005 Oct;27(10):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review.
  • The authors describe a 4-year-old girl with acute lymphoblastic leukemia in remission who developed fulminant hepatic failure due to varicella-zoster virus (VZV).
  • [MeSH-major] Chickenpox / virology. Hepatitis, Viral, Human / virology. Herpesvirus 3, Human / isolation & purification. Liver Failure, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217259.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Brassesco MS, Montaldi AP, Gras DE, Camparoto ML, Martinez-Rossi NM, Scrideli CA, Tone LG, Sakamoto-Hojo ET: Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukaemia survivors. Mutagenesis; 2009 Mar;24(2):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukaemia survivors.
  • The successful treatment of paediatric malignancies by multimodal therapy has improved outcomes for children with cancer, especially those with acute lymphoblastic leukaemia (ALL).
  • Depending on dosage, 2-12% of patients treated with topoisomerase II inhibitors and/or alkylating agents develop treatment-related acute myeloid leukaemia characterized by translocations at 11q23.
  • Even though the biological significance of these rearrangements needs further investigation, they demonstrate a degree of genome instability, indicating the relevance of cytogenetic and molecular studies during the follow-up of patients in complete clinical remission.
  • [MeSH-major] Cytogenetic Analysis. Gene Rearrangement. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Survivors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028982.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide; 957E6438QA / Teniposide
  •  go-up   go-down


78. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • Haematological remission was obtained on day 33 of induction treatment (on time).
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


79. Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M: FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. J Pak Med Assoc; 2005 Jun;55(6):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
  • OBJECTIVE: To evaluate the efficacy and toxicity profile of the combination of fludarabine, high dose cytarabine, idarubicin, and granulocyte colony stimulating factor in refractory relapsed cases of acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003.
  • METHODS: Twelve Patients with refractory/relapsed (Ref/Rel) acute leukaemia (AL) were treated with fludarabine 30 mg/m2 and cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10 mg/m2 for 3 days, and granulocyte colony stimulating factor G-CSF 5 micro g/kg from day 0 till neutrophil recovery (ANC > 1.0 x 10(9)/1).
  • RESULTS: Patients included were refractory acute lymphoblastic leukaemia (ALL) (n=2), relapsed ALL (n = 3), refractory acute myeloid leukaemia (AML) (n = 3), secondary AML (n=2) relapsed AML (n = 1) and acute undifferentiated leukaemia (AUL) (n = 1).
  • Complete remission (CR) was achieved in 8 (66.6%) patients.
  • Three (25%) patients died of post chemotherapy complications and one patient failed to achieve remission.
  • Out of 8 patients who achieved CR, 4 underwent allogeneic bone marrow transfusion (BMT), 1 is being evaluated for the same, 1 received idorubicin, AraC and etopuside (ICE) and high dose AraC, 1 did not receive further chemotherapy and 1 relapsed two months after remission.
  • CONCLUSION: In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed/refractory acute leukaemias.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Child. Cytarabine / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045091.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


80. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood; 2006 Jul 15;108(2):465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
  • Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear.
  • We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase.
  • Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy.
  • Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL.
  • Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis.
  • Overall survival at 5 years was 29% in those with CNS involvement at diagnosis versus 38% (P = .03) for those without.
  • CNS leukemia in adult ALL is uncommon at diagnosis.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):94-100 [7803263.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2017-25 [10811665.001]
  • [Cites] Leukemia. 2001 Feb;15(2):208-16 [11236936.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):191-4 [3528788.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Blood. 1989 Jan;73(1):57-63 [2642717.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:175-7 [1578926.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:49-51 [1434832.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1990-2001 [8410124.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • (PMID = 16556888.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1895498
  •  go-up   go-down


81. de Koning HD, Bodar EJ, van der Meer JW, Simon A, Schnitzler Syndrome Study Group: Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum; 2007 Dec;37(3):137-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain, and lymphadenopathy.
  • There have been promising developments in therapeutic options, especially antiinterleukin-1 treatment, which induced complete remission in all 8 patients treated so far.
  • However, they had a 10-year risk of 15% of developing a lymphoproliferative disorder, most notably Waldenström's macroglobulinemia.
  • CONCLUSIONS: Schnitzler syndrome is a disabling disorder which affects multiple systems and which can be considered as an autoinflammatory syndrome.
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Prognosis. Risk Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Semin Arthritis Rheum. 2008 Oct;38(2):163; author reply 164 [18304609.001]
  • (PMID = 17586002.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


82. Ottmann OG, Pfeifer H: First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
  • The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561414.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; RBZ1571X5H / Dasatinib
  • [Number-of-references] 26
  •  go-up   go-down


83. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • BACKGROUND: Acute leukaemia is a group of rapidly progressing cancers of bone marrow and blood classified as either acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


84. Nowicki M, Ostalska-Nowicka D, Kaczmarek E, Miskowiak B, Witt M: Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. Histopathology; 2006 Aug;49(2):170-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach.
  • AIMS: To investigate the immunocytochemical expression of vascular endothelial growth factor C (VEGF-C) and its receptors (VEGFR-2 and VEGFR-3) in childhood acute lymphoblastic leukaemia (ALL) blasts and to determine the possible role of this complex in the pathogenesis and prognosis of ALL.
  • CONCLUSIONS: The absence of VEGF-C in blast cells predicts long-lasting remission in all leukaemic children.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vascular Endothelial Growth Factor C / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879394.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


85. Al-Tonbary Y, Mansour AK, Ghazy H, Elghannam DM, Abd-Elghaffar HA: Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia. Int J Lab Hematol; 2009 Jun;31(3):320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
  • In children with acute myelogenous leukaemia (AML), internal tandem duplication of the Flt3 gene (Flt3/ITD) was previously reported and correlated to poor prognosis.
  • Limited data are available about childhood acute lymphoblastic leukaemia (ALL).
  • We analysed bone marrow specimens from 55 newly diagnosed acute leukaemia cases including 30 AML and 25 ALL by genomic PCR for the presence of Flt3/ITD and correlated its presence with clinical outcome.
  • Complete remission was achieved in 16.6% of cases with duplication vs. 45.8% in cases without duplication.
  • Failure to achieve induction remission was noted in 50% of cases with duplication vs. 29.1% in cases without duplication.
  • Patients with Flt3/ITD appear to be refractory to primary induction therapy, and for those who achieve remission, there is a high rate of relapse and death so there may be an association between this type of mutation and patient outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Egypt / epidemiology. Female. Gene Duplication. Gene Frequency / genetics. Humans. Infant. Male. Multivariate Analysis. Mutation / genetics. Prognosis. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336585.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


86. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Dombret H, Thomas X, GET-LALA Group, Swiss Group for Clinical Cancer Research SAKK, Australasian Leukaemia and Lymphoma Group: Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia; 2007 Sep;21(9):1907-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.
  • Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse.
  • One hundred and eighty-seven patients (44%) achieved a second complete remission (CR).
  • Risk groups defined at diagnosis and treatment received in first CR did not influence the outcome after relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Risk Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611565.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


87. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant; 2006 Jan;37(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
  • We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT.
  • The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3).
  • The median time between diagnosis and transplantation was 5 months (range, 3-86).
  • Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs non-CR1: 3 years: 48 vs 89%; P = 0.05).
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Graft Survival. Humans. Incidence. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous


88. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A, Rowe J, Webb D: Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer; 2007 Mar;48(3):254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
  • BACKGROUND: Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL.
  • Multivariate analysis allowing for age and Ph status, diminished the EFS difference, but confirmed a reduced rate of death in remission in patients managed on the paediatric protocol.
  • [MeSH-major] Adolescent. Age Factors. Patient Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Bone Marrow Transplantation. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prognosis. Remission Induction. Research Design. Survival Analysis. Thioguanine / administration & dosage. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Teens' Page.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16421910.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


89. Keles B, Duran M, Uyar Y, Azimov A, Demirkan A, Esen HH: Juvenile ossifying fibroma of the mandible: a case report. J Oral Maxillofac Res; 2010;1(2):e5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the history of the patient there has been an acute lymphocytic leukaemia in the remission for 3 years.
  • CONCLUSIONS: Although juvenile ossifying fibroma is an uncommon clinical entity, its aggressive local behaviour and high recurrence rate means that it is important to make an early diagnosis, apply the appropriate treatment and, especially, follow-up the patient over the long-term.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24421970.001).
  • [ISSN] 2029-283X
  • [Journal-full-title] Journal of oral & maxillofacial research
  • [ISO-abbreviation] J Oral Maxillofac Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Lithuania
  • [Other-IDs] NLM/ PMC3886046
  • [Keywords] NOTNLM ; lymphocytic leukemia. / mandibular diseases / mandibular neoplasms / oral surgery / ossifying fibroma
  •  go-up   go-down


90. Chowdhury S, Bandyopadhyay S, Chandra S, Mandal C: Comparative analysis of differential expression of sialic acids and adhesion molecules on mononuclear cells of bone marrow and peripheral blood in childhood acute lymphoblastic leukaemia at diagnosis and clinical remission. Indian J Biochem Biophys; 2007 Oct;44(5):357-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of differential expression of sialic acids and adhesion molecules on mononuclear cells of bone marrow and peripheral blood in childhood acute lymphoblastic leukaemia at diagnosis and clinical remission.
  • Childhood acute lymphoblastic leukaemia (ALL) is characterized by the neoplasm of immature haematopoietic precursor cells (HPCs).
  • We report significant differences between the expression of sialoglycoproteins and adhesion molecules on mononuclear cells (MNCs) of bone marrow (BM) and peripheral blood (PB) from individual children at diagnosis of the disease.
  • Diverse trend of these cell surface macromolecules was observed during clinical remission.
  • [MeSH-major] Bone Marrow Cells / metabolism. Cell Adhesion Molecules / metabolism. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sialic Acids / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341211.001).
  • [ISSN] 0301-1208
  • [Journal-full-title] Indian journal of biochemistry & biophysics
  • [ISO-abbreviation] Indian J. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Sialic Acids
  •  go-up   go-down


91. Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panes J: Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol; 2007 Apr 21;13(15):2193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective was clinical remission at wk 17.
  • Secondary measures included endoscopic remission and steroid consumption.
  • At wk 17, 37.5% of patients in group 1 and 45.45% of patients in group 2 were in clinical remission.
  • Clinical remission was accompanied by endoscopic remission in all cases.
  • Eighty-six percent of patients achieving remission were steroid-free at wk 17.
  • Eighty-nine per cent of patients remained in remission during a one year follow-up.
  • In this population, increasing the number of aphaeresis sessions is not associated with higher remission rates, but affords a significant steroid-sparing effect.
  • [MeSH-minor] Adolescent. Adult. Aged. Endpoint Determination. Female. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies. Remission Induction / methods. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1362-9 [15929771.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1805-11 [15940615.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2462-76 [16339095.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):255-60 [11487534.001]
  • [Cites] Gut. 2002 Apr;50(4):485-9 [11889067.001]
  • [Cites] Curr Pharm Des. 2003;9(4):307-21 [12570823.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52 [15606397.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):565-71 [15185858.001]
  • [Cites] Inflamm Bowel Dis. 2004 May;10(3):251-7 [15290920.001]
  • [Cites] Digestion. 2004;70(1):36-44 [15297776.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct 1;20(7):783-92 [15379839.001]
  • [Cites] BMJ. 1989 Jan 14;298(6666):82-6 [2563951.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1998 Jun;30(3):338-44 [9759608.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jan;1(1):28-35 [15017514.001]
  • (PMID = 17465500.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Steroids
  • [Other-IDs] NLM/ PMC4146843
  •  go-up   go-down


92. El aichaoui S, Bahiri R, Benbouazza K, Bzami F, Amine B, Allali F, Hajjaj-Hassouni N: [Leukemia revealed by polyarthritis]. Rev Med Interne; 2006 Jul;27(7):555-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukemia revealed by polyarthritis].
  • INTRODUCTION: Ostéoarticular manifestation whose reveal leukaemia in 4% of the cases, regress completely with haematological remission.
  • EXEGESIS: We report two observations of leukaemia revealed by polyarthritis.
  • A 22-year-old woman has presented a polyarthritis 8 months before de diagnosis of acute leukaemia.
  • A 34 years old men, has presented one month before admission an acute polyarthritis revealing chronic myeloid leukaemia.
  • CONCLUSION: Polyarthritis may reveal an acute or chronic leukaemia.
  • Systematic blood analysis can make a difference in diagnosis of recent polyarthritis.

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750282.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D: Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol; 2009 Feb;10(2):147-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
  • BACKGROUND: About a fifth of children with acute T-lymphoblastic leukaemia (T-ALL) succumb to the disease, suggesting an unrecognised biological heterogeneity that might contribute to drug resistance.
  • We postulated that T-ALL originating from early T-cell precursors (ETPs), a recently defined subset of thymocytes that retain stem-cell-like features, would respond poorly to lymphoid-cell-directed therapy.
  • We studied leukaemic cells, collected at diagnosis, to identify cases with ETP features and determine their clinical outcome.
  • Patients with this form of leukaemia had high risk of remission failure or haematological relapse (72% [95% CI 40-100] at 10 years vs 10% [4-16] at 10 years for patients with typical T-ALL treated at St Jude Children's Research Hospital; and 57% [25-89] at 2 years vs 14% [6-22] at 2 years for patients treated in the AIEOP trial).

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Mar 1;105(5):1930-6 [15522952.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3131-7 [16384926.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5742-9 [17179108.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):421-38 [17579063.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):9-21 [18097446.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):768-72 [18401412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1696-707 [10557041.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] Blood. 1990 Jan 1;75(1):166-73 [1688495.001]
  • [Cites] Leukemia. 1993 Jan;7(1):35-40 [8418377.001]
  • [Cites] Blood. 1993 Aug 1;82(3):889-94 [7687897.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1684-93 [8826928.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2214-21 [9196133.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Blood. 1998 Jul 15;92(2):596-9 [9657760.001]
  • [CommentIn] Lancet Oncol. 2009 Feb;10(2):105-6 [19185830.001]
  • (PMID = 19147408.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA060419-12; United States / NCI NIH HHS / CA / R01 CA060419-12; United States / NCI NIH HHS / CA / CA060419-10; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA060419-11; United States / NCI NIH HHS / CA / R01 CA060419-10; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA060419-11; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS118479; NLM/ PMC2840241
  •  go-up   go-down


94. Masuko M, Furukawa T, Yersser O, Narita M, Toba K, Koike T, Aizawa Y: Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection. Leuk Res; 2005 Sep;29(9):1083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection.
  • A 16-year-old boy in a second remission of acute lymphoblastic leukemia (ALL) had undergone transplantation of bone marrow from an unrelated donor.
  • Although the donor marrow was rejected, hematopoiesis by the recipient himself recovered and he has remained in complete remission for more than 8 years after stem cell transplantation (SCT).
  • Although complete remission was maintained, various chromosomal aberrations were detected in marrow cells, and in peripheral blood cells under phytohemagglutinin stimulation over 8 years.
  • This persistence of various chromosomal aberrations and a stable clone without evolution to myelodysplastic syndrome or leukemia support the multi step theory of leukemogenesis.
  • [MeSH-major] Bone Marrow Transplantation. Chromosome Aberrations. Graft Rejection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038736.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Moses T, Leuchter AF, Cook I, Abrams M: Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis; 2006 Apr;194(4):241-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that QOL did not normalize along with clinical remission in all areas.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Depressive Disorder, Major / diagnosis. Depressive Disorder, Major / drug therapy. Morpholines / therapeutic use. Quality of Life / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. REBOXETINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614544.001).
  • [ISSN] 0022-3018
  • [Journal-full-title] The Journal of nervous and mental disease
  • [ISO-abbreviation] J. Nerv. Ment. Dis.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / T32 MH 017140-20
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Morpholines; 947S0YZ36I / reboxetine
  •  go-up   go-down


96. Carret AS, Tabori U, Crooks B, Hukin J, Odame I, Johnston DL, Keene DL, Freeman C, Bouffet E, Canadian Pediatric Brain Tumour Consortium: Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium. Radiother Oncol; 2006 Oct;81(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to review the pattern of diagnosis, the treatment, and outcome of secondary pediatric HGG.
  • All patients had previously received radiation therapy +/- chemotherapy for either acute lymphoblastic leukaemia (n=9) or solid tumour (n=9).
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / mortality. Astrocytoma / therapy. Canada. Child. Female. Humans. Male. Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Remission Induction. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16973227.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


97. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA 3rd, Weitman S: Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov; 2006 Oct;5(10):855-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of acute leukaemias, which are the most common paediatric cancers, has improved considerably in recent decades, with complete response rates approaching approximately 90% in some cases.
  • However, there remains a major need for treatments for patients who do not achieve or maintain complete remission, for whom the prognosis is very poor.
  • In this article, we describe the challenges involved in the discovery and development of clofarabine, a second-generation nucleoside analogue that received accelerated approval from the US FDA at the end of 2004 for the treatment of paediatric patients 1-21 years old with relapsed or refractory acute lymphoblastic leukaemia after at least two prior regimens.
  • It is the first such drug to be approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use.
  • [MeSH-minor] Clinical Trials as Topic. Drug Approval. Humans. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016426.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 60
  •  go-up   go-down


98. Barbaric D, Corthals SL, Jastaniah WA, Asalanian S, Shimizu H, Reid GS, Schultz KR: Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. Br J Haematol; 2008 Apr;141(2):271-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocyte Subsets / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Child, Preschool. Humans. Interferon-gamma / biosynthesis. Remission Induction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307567.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


99. Stam RW, den Boer ML, Pieters R: Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol; 2006 Mar;132(5):539-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards targeted therapy for infant acute lymphoblastic leukaemia.
  • Despite the greatly improved treatment regimes for childhood acute lymphoblastic leukaemia (ALL) in general, resulting in long-term survival in approximately 80% of cases, current therapies still fail in >50% of ALL cases diagnosed within the first year of life (i.e. in infants).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Age of Onset. Forecasting. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Mutation. Myeloid-Lymphoid Leukemia Protein / genetics. Prognosis. Remission Induction. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445826.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 139
  •  go-up   go-down


100. Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, Pötschger U, Ullmann R, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer R, Strehl S, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. Br J Haematol; 2010 Jan;148(2):293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
  • TLX3 expression (TLX3+) in childhood T-cell acute lymphoblastic leukaemia (T-ALL) seems to be associated with a poor prognosis when treated with regimens that lack early and/or late re-intensification therapy elements.
  • The male to female ratio was 3.5:1 and median age and leucocyte count at diagnosis were 8.7 years and 58.9 x 10(9)/l, respectively.
  • All were in complete remission after induction therapy.
  • After a median observation time of 4.9 years (range 0.4-16.1 years) 28/31 TLX3+ cases remained in first complete remission after chemotherapy with one after additional stem cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Homeodomain Proteins / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821827.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TLX3 protein, human; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down






Advertisement